Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohammad H Alshaer

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Therapeutic Drug Monitoring|October 3, 2025
Cefepime Pharmacokinetics in Patients Receiving Extracorporeal Membrane OxygenationNicole F Maranchick, Andrew Jaudon, Siya Aparanji, et al.
Antimicrobial Agents and Chemotherapy|June 14, 2022
Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated PneumoniaMohammad H Alshaer, Nicole Maranchick, Chen Bai, et al.
Frontiers in Pharmacology|December 29, 2022
Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitisNicole F Maranchick, Mohammad H Alshaer, Alison G C Smith, et al.
Critical Care Explorations|February 2, 2024
Cefepime Daily Exposure and the Associated Impact on the Change in Sequential Organ Failure Assessment Scores and Vasopressors Requirement in Critically Ill Patients Using Repeated-Measures Mixed-Effect ModelingMohammad H Alshaer, Roy Williams, Mays J Mousa, et al.
International Journal of Antimicrobial Agents|July 30, 2023
The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongationYutong Jin, David Benkeser, Maia Kipiani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 1, 2021
Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential UsefulnessRussell R Kempker, Alison G C Smith, Teona Avaliani, et al.
Clinical Pharmacokinetics|June 28, 2022
Clinical Pharmacokinetics and Pharmacodynamics of CefepimeGwendolyn M Pais, Jack Chang, Erin F Barreto, et al.
Implementation Science Communications|March 25, 2021
Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods studyErin F Barreto, Andrew D Rule, Mohammad H Alshaer, et al.
Antimicrobial Agents and Chemotherapy|August 2, 2022
Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant TuberculosisDaniel S Graciaa, Maia Kipiani, Matthew J Magee, et al.
Antimicrobial Agents and Chemotherapy|December 13, 2021
Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population PharmacokineticsMohammad H Alshaer, Sylvain Goutelle, Barbara A Santevecchi, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Therapeutic Drug Monitoring|October 3, 2025
Cefepime Pharmacokinetics in Patients Receiving Extracorporeal Membrane OxygenationNicole F Maranchick, Andrew Jaudon, Siya Aparanji, et al.
Antimicrobial Agents and Chemotherapy|June 14, 2022
Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated PneumoniaMohammad H Alshaer, Nicole Maranchick, Chen Bai, et al.
Frontiers in Pharmacology|December 29, 2022
Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitisNicole F Maranchick, Mohammad H Alshaer, Alison G C Smith, et al.
Critical Care Explorations|February 2, 2024
Cefepime Daily Exposure and the Associated Impact on the Change in Sequential Organ Failure Assessment Scores and Vasopressors Requirement in Critically Ill Patients Using Repeated-Measures Mixed-Effect ModelingMohammad H Alshaer, Roy Williams, Mays J Mousa, et al.
International Journal of Antimicrobial Agents|July 30, 2023
The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongationYutong Jin, David Benkeser, Maia Kipiani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 1, 2021
Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential UsefulnessRussell R Kempker, Alison G C Smith, Teona Avaliani, et al.
Clinical Pharmacokinetics|June 28, 2022
Clinical Pharmacokinetics and Pharmacodynamics of CefepimeGwendolyn M Pais, Jack Chang, Erin F Barreto, et al.
Implementation Science Communications|March 25, 2021
Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods studyErin F Barreto, Andrew D Rule, Mohammad H Alshaer, et al.
Antimicrobial Agents and Chemotherapy|August 2, 2022
Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant TuberculosisDaniel S Graciaa, Maia Kipiani, Matthew J Magee, et al.
Antimicrobial Agents and Chemotherapy|December 13, 2021
Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population PharmacokineticsMohammad H Alshaer, Sylvain Goutelle, Barbara A Santevecchi, et al.
Pageof 3